@article{8b69ec84eae44294830ce7c730cd825b,
title = "Combination GnRH antagonists for endometriosis: balancing efficacy with side-effects",
author = "Whitaker, \{Lucy H R\} and L. Saraswat and Horne, \{Andrew W\}",
note = "Funding Information: L.H.R.W. receives grant funding from the National Institute for Health Research (NIHR) and the Chief Scientist's Office. A.W.H. receives grant funding from the NIHR, the Medical Research Council (MRC), the Chief Scientist's Office, and Roche. L.H.R.W. and A.W.H. are supported by an MRC Center Grant (MRC G1002033). L.S. reports a grant from NIHR and from EU Horizon 2020 unrelated to the topic of this Spotlight. A.W.H. has received honoraria for consultancy for Ferring, Roche, Nordic Pharma, and Abbvie. L.S. has received an honorarium from Gideon-Richter for attending one advisory board meeting on the use of relugolix combination therapy in the management of fibroids. Funding Information: L.H.R.W. receives grant funding from the National Institute for Health Research ( NIHR ) and the Chief Scientist{\textquoteright}s Office. A.W.H. receives grant funding from the NIHR , the Medical Research Council ( MRC ), the Chief Scientist{\textquoteright}s Office, and Roche . L.H.R.W. and A.W.H. are supported by an MRC Center Grant ( MRC G1002033 ). L.S. reports a grant from NIHR and from EU Horizon 2020 unrelated to the topic of this Spotlight. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = sep,
day = "20",
doi = "10.1016/j.xcrm.2022.100748",
language = "English",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
}